MD3233862T2 - Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta - Google Patents
Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3ΚbetaInfo
- Publication number
- MD3233862T2 MD3233862T2 MDE20170191T MD3233862T2 MD 3233862 T2 MD3233862 T2 MD 3233862T2 MD E20170191 T MDE20170191 T MD E20170191T MD 3233862 T2 MD3233862 T2 MD 3233862T2
- Authority
- MD
- Moldova
- Prior art keywords
- inhibitors
- compounds
- pi3kbeta
- imidazopyridazine derivatives
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199322 | 2014-12-19 | ||
PCT/EP2015/080604 WO2016097347A1 (en) | 2014-12-19 | 2015-12-18 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3233862T2 true MD3233862T2 (ro) | 2019-11-30 |
Family
ID=52134002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20170191 MD3233862T2 (ro) | 2014-12-19 | 2015-12-18 | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta |
Country Status (25)
Country | Link |
---|---|
US (1) | US10087187B2 (es) |
EP (1) | EP3233862B1 (es) |
JP (1) | JP6568588B2 (es) |
KR (1) | KR20170095239A (es) |
CN (1) | CN107108634B (es) |
AU (1) | AU2015366190B2 (es) |
BR (1) | BR112017012930A2 (es) |
CA (1) | CA2967551A1 (es) |
CY (1) | CY1122381T1 (es) |
DK (1) | DK3233862T3 (es) |
EA (1) | EA029789B1 (es) |
ES (1) | ES2761051T3 (es) |
HR (1) | HRP20191550T1 (es) |
HU (1) | HUE045220T2 (es) |
IL (1) | IL252866B (es) |
LT (1) | LT3233862T (es) |
MA (1) | MA41174B1 (es) |
MD (1) | MD3233862T2 (es) |
ME (1) | ME03517B (es) |
MX (1) | MX2017008074A (es) |
PL (1) | PL3233862T3 (es) |
PT (1) | PT3233862T (es) |
RS (1) | RS59301B1 (es) |
SI (1) | SI3233862T1 (es) |
WO (1) | WO2016097347A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037401B1 (ru) | 2015-10-09 | 2021-03-24 | Янссен Фармацевтика Нв | Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k |
LT3472160T (lt) | 2016-06-16 | 2021-04-26 | Janssen Pharmaceutica Nv | Biciklinio piridino, pirazino ir pirimidino dariniai kaip pi3k beta inhibitoriai |
AU2018246321B2 (en) | 2017-03-29 | 2021-07-29 | Janssen Pharmaceutica Nv | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors |
CN110128505A (zh) * | 2019-05-21 | 2019-08-16 | 梯尔希(南京)药物研发有限公司 | 一种戈舍瑞林杂质的合成方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US20090215818A1 (en) | 2006-07-24 | 2009-08-27 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as pi3 kinase inhibitors |
CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
MX2009012066A (es) * | 2007-05-09 | 2009-11-19 | Novartis Ag | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. |
WO2009060197A1 (en) * | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
WO2009106577A1 (en) * | 2008-02-28 | 2009-09-03 | Novartis Ag | Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
ES2709108T3 (es) | 2009-08-17 | 2019-04-15 | Intellikine Llc | Compuestos heterocíclicos y usos de los mismos |
DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
EP2624696B1 (en) | 2010-10-06 | 2016-12-21 | Glaxosmithkline LLC | Benzimidazole derivatives as pi3 kinase inhibitors |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
US9096605B2 (en) * | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
WO2013095761A1 (en) | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途 |
GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
-
2015
- 2015-12-18 EA EA201791396A patent/EA029789B1/ru not_active IP Right Cessation
- 2015-12-18 WO PCT/EP2015/080604 patent/WO2016097347A1/en active Application Filing
- 2015-12-18 EP EP15810784.7A patent/EP3233862B1/en active Active
- 2015-12-18 MA MA41174A patent/MA41174B1/fr unknown
- 2015-12-18 SI SI201530855T patent/SI3233862T1/sl unknown
- 2015-12-18 RS RSP20191225 patent/RS59301B1/sr unknown
- 2015-12-18 JP JP2017532819A patent/JP6568588B2/ja not_active Expired - Fee Related
- 2015-12-18 AU AU2015366190A patent/AU2015366190B2/en not_active Ceased
- 2015-12-18 ES ES15810784T patent/ES2761051T3/es active Active
- 2015-12-18 BR BR112017012930A patent/BR112017012930A2/pt active Search and Examination
- 2015-12-18 US US15/537,551 patent/US10087187B2/en active Active
- 2015-12-18 DK DK15810784.7T patent/DK3233862T3/da active
- 2015-12-18 MD MDE20170191 patent/MD3233862T2/ro unknown
- 2015-12-18 MX MX2017008074A patent/MX2017008074A/es active IP Right Grant
- 2015-12-18 HU HUE15810784A patent/HUE045220T2/hu unknown
- 2015-12-18 PT PT158107847T patent/PT3233862T/pt unknown
- 2015-12-18 PL PL15810784T patent/PL3233862T3/pl unknown
- 2015-12-18 LT LTEP15810784.7T patent/LT3233862T/lt unknown
- 2015-12-18 CN CN201580069133.7A patent/CN107108634B/zh not_active Expired - Fee Related
- 2015-12-18 CA CA2967551A patent/CA2967551A1/en active Pending
- 2015-12-18 KR KR1020177016722A patent/KR20170095239A/ko not_active Application Discontinuation
- 2015-12-18 ME MEP-2019-263A patent/ME03517B/me unknown
-
2017
- 2017-06-13 IL IL252866A patent/IL252866B/en active IP Right Grant
-
2019
- 2019-08-28 HR HRP20191550 patent/HRP20191550T1/hr unknown
- 2019-10-03 CY CY20191101031T patent/CY1122381T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EA201791396A1 (ru) | 2017-10-31 |
CY1122381T1 (el) | 2021-01-27 |
HUE045220T2 (hu) | 2019-12-30 |
BR112017012930A2 (pt) | 2018-01-09 |
SI3233862T1 (sl) | 2019-09-30 |
IL252866A0 (en) | 2017-08-31 |
EP3233862A1 (en) | 2017-10-25 |
US20180002336A1 (en) | 2018-01-04 |
EP3233862B1 (en) | 2019-07-03 |
MA41174B1 (fr) | 2019-09-30 |
MA41174A (fr) | 2017-10-25 |
CA2967551A1 (en) | 2016-06-23 |
CN107108634A (zh) | 2017-08-29 |
PL3233862T3 (pl) | 2020-01-31 |
EA029789B1 (ru) | 2018-05-31 |
MX2017008074A (es) | 2018-01-09 |
LT3233862T (lt) | 2019-09-10 |
KR20170095239A (ko) | 2017-08-22 |
ES2761051T3 (es) | 2020-05-18 |
HRP20191550T1 (hr) | 2019-11-29 |
JP2017538734A (ja) | 2017-12-28 |
AU2015366190B2 (en) | 2020-01-23 |
IL252866B (en) | 2020-09-30 |
JP6568588B2 (ja) | 2019-08-28 |
RS59301B1 (sr) | 2019-10-31 |
PT3233862T (pt) | 2019-10-09 |
AU2015366190A1 (en) | 2017-05-25 |
US10087187B2 (en) | 2018-10-02 |
DK3233862T3 (da) | 2019-10-07 |
CN107108634B (zh) | 2020-09-15 |
ME03517B (me) | 2020-04-20 |
WO2016097347A1 (en) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3341368T2 (ro) | Noi analogi nucleozidici substituiți сu un inel aromatic biciclic 6-6 pentru utilizare ca inhibitori ai PRMT5 | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
MD3472167T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MD3468971T2 (ro) | Noi derivați de piperidinil (hetero)aril-substituiţi, procedeu de obţinere a acestora și compoziții farmaceutice care îi conțin | |
MD3377488T2 (ro) | Compuși heterociclici ca imunomodulatori | |
EA201892734A1 (ru) | ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA | |
PH12017502001A1 (en) | Amido-substituted cyclohexane derivatives | |
MD3313849T2 (ro) | Noi derivați de hidroxiacid, procedeu de preparare a acestora și compoziții farmaceutice care îi conțin | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
MD3313851T2 (ro) | Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
MD3313850T2 (ro) | Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
EA201692003A1 (ru) | Макроциклические производные пиримидина | |
EA201692000A1 (ru) | Макроциклические производные пиридина | |
EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
EA201500931A1 (ru) | Производные пиридин-4-ила | |
MD3233827T2 (ro) | Compuși antibacterieni cu spectru larg de activitate | |
MD3303331T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
CY1121063T1 (el) | Αναστολεις της συνθασης της αλδοστερονης | |
EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
MD3233862T2 (ro) | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta | |
PH12015502747A1 (en) | Novel compounds for the treatment of cancer | |
EA201691962A1 (ru) | Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2 |